GeNeuro SA (EPA:GNRO)

Market Cap	911.56K -56.0%
Revenue (ttm)	n/a
Net Income	-14.76M
EPS	-0.59
Shares Out	29.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.0308
Day's Range	n/a
52-Week Range	0.0198 - 0.1240
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2026

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 17
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNRO

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

May 12, 2026

Data Sources Report a data error